GETI.B

192.05

-0.36%↓

CAMX

655.5

-3.03%↓

VITR

137

-1.23%↓

ATT

68.8

-1.01%↓

ARJOB

33.12

-0.9%↓

GETI.B

192.05

-0.36%↓

CAMX

655.5

-3.03%↓

VITR

137

-1.23%↓

ATT

68.8

-1.01%↓

ARJOB

33.12

-0.9%↓

GETI.B

192.05

-0.36%↓

CAMX

655.5

-3.03%↓

VITR

137

-1.23%↓

ATT

68.8

-1.01%↓

ARJOB

33.12

-0.9%↓

GETI.B

192.05

-0.36%↓

CAMX

655.5

-3.03%↓

VITR

137

-1.23%↓

ATT

68.8

-1.01%↓

ARJOB

33.12

-0.9%↓

GETI.B

192.05

-0.36%↓

CAMX

655.5

-3.03%↓

VITR

137

-1.23%↓

ATT

68.8

-1.01%↓

ARJOB

33.12

-0.9%↓

Search

Vivesto AB

Aperta

0

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

Metriche Chiave

By Trading Economics

Entrata

2.4M

-8.3M

EPS

-0.015

Dipendenti

4

Dividendi

By Dow Jones

Utili prossimi

12 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

4.6M

128M

Apertura precedente

0

Chiusura precedente

0

Vivesto AB Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

5 ago 2025, 23:11 UTC

Utili

Australia's REA Hikes Dividend as Annual Profit Rises 23% -- Update

5 ago 2025, 22:45 UTC

Utili

Australia's REA Hikes Dividend as Annual Profit Rises 23%

5 ago 2025, 22:39 UTC

Utili

Great-West Lifeco Logs Lower 2Q Profit

5 ago 2025, 21:32 UTC

Utili

Coupang Posts Higher 2Q Sales Due to Customer Growth

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

NFL to Take 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

The NFL Is Taking a 10% Stake in Disney's ESPN -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Disney to Take Control of NFL Network as Part of Agreement -- WSJ

6 ago 2025, 00:00 UTC

Acquisizioni, Fusioni, Takeovers

Disney, NFL Strike Wide-Reaching Media-Asset Deal -- WSJ

5 ago 2025, 23:48 UTC

Discorsi di Mercato

Nikkei May Decline Amid U.S. Economic Uncertainty -- Market Talk

5 ago 2025, 23:40 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Fed Rate-Cut Hopes -- Market Talk

5 ago 2025, 23:19 UTC

Discorsi di Mercato

Lindian Deal With Iluka Demonstrates Kangankunde Project Appeal -- Market Talk

5 ago 2025, 23:03 UTC

Discorsi di Mercato
Utili

Advanced Micro Devices' Data-Center Story Seen as Promising -- Market Talk

5 ago 2025, 22:22 UTC

Utili

REA: Expectation of More Interest-Rate Cuts Likely to Support Buyer Demand>REA.AU

5 ago 2025, 22:21 UTC

Utili

REA Expects FY26 Listing Volumes Broadly Flat on FY25>REA.AU

5 ago 2025, 22:20 UTC

Utili

REA Expects September-Quarter Listings to Be Down on Year>REA.AU

5 ago 2025, 22:18 UTC

Utili

REA July 2025 New Residential Listings Down 8% on Year>REA.AU

5 ago 2025, 22:17 UTC

Utili

REA FY25 Australian Residential Listings Up 1% on Year>REA.AU

5 ago 2025, 22:17 UTC

Utili

REA FY25 India Revenue A$129M Vs. A$103M>REA.AU

5 ago 2025, 22:16 UTC

Utili

REA FY25 Core Australia Revenue A$1.54B Vs. A$1.35B>REA.AU

5 ago 2025, 22:16 UTC

Utili

REA FY25 Core Operations Net Profit A$564.4M Vs. A$460.5M>REA.AU

5 ago 2025, 22:15 UTC

Utili

REA Group FY25 Ebitda A$969.2M Vs. A$824.8M>REA.AU

5 ago 2025, 22:13 UTC

Utili

REA Group Raises Dividend to A$1.38 Vs. A$1.02 >REA.AU

5 ago 2025, 22:13 UTC

Utili

REA Group FY25 Rev A$1.67B Vs. A$1.45B >REA.AU

5 ago 2025, 22:12 UTC

Utili

REA FY25 Core Operations Net Profit A$564.4M Vs, A$460.5M>REA.AU

5 ago 2025, 22:12 UTC

Utili

REA Group FY25 Net A$677.9M Vs. Net A$302.8M >REA.AU

5 ago 2025, 21:58 UTC

Utili

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

5 ago 2025, 21:30 UTC

Utili

AMD Gives a Strong Outlook. Why the Stock Is Falling. -- Barrons.com

5 ago 2025, 21:26 UTC

Utili

AMD CEO Expects Embedded Segment to Return to Sequential Growth in Back Half of 2025

5 ago 2025, 21:23 UTC

Utili

AMD CEO Sees Strong Customer Interest in MI400 Series for Large-Scale Deployments

5 ago 2025, 21:17 UTC

Utili

AMD Expects Steep Production Ramp for MI350 Series in Back Half of Year, CEO Says

Confronto tra pari

Modifica del prezzo

Vivesto AB Previsione

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.